Immunization with recombinant S. pneumoniae neuraminidase NanA (rNanA) resulted in a significant reduction in pneumococcal colonization in the chinchilla model. The bacteria were eliminated from the nasopharynx 1 week earlier than that from the control cohort. Our data suggest that rNanA affords protection against pneumococcal nasopharyngeal colonization.
face protein A (PspA), pneumococcal surface adhesion A (PsaA), choline binding protein A (CbpA), and pyruvate oxidase (SpxB) have each been shown to play roles in NP colonization (21) and immunization, with some of these proteins eliciting protection against carriage in animal models (3, 23) .
Considerable evidence from our laboratories and others' has implicated S. pneumoniae neuraminidase as a virulence factor in the pathogenesis of OM (13, 14, 15, 29, 31) . Neuraminidase is an enzyme that cleaves N-acetylneuraminic acid from mucin, glycolipids, glycoproteins, and oligosaccharides on host cell surfaces. All S. pneumoniae isolates to date have been shown to produce neuraminidase (11) . S. pneumoniae neuraminidase has been detected in 78% of culture-positive human middle ear effusions from patients with acute OM and in 96% of S. pneumoniae-positive middle ear effusions from patients who have chronic OM with effusion (8) . We have shown that the ability of the nanA mutant to colonize and persist within the nasopharynx and middle ear is significantly impaired relative to the parent strain (27) . Most recently, we have reported that immunization with native S. pneumoniae neuraminidase or recombinant NanA (rNanA) protects the chinchilla against OM after intranasal (i.n.) challenge with S. pneumoniae after a prior influenza A virus infection, which is the most reliable way of establishing OM in the chinchilla via the intranasal route (17) . To what extent the immunization with rNanA affects S. pneumoniae nasopharyngeal colonization kinetics without an antecedent viral infection is not known. This study was designed to investigate the full effect of immunization with rNanA on the course of S. pneumoniae NP colonization in order to determine the potential for NanA to serve as a protein-based vaccine candidate.
Bacteria. S. pneumoniae 6A (EF3114, kindly provided by B. Anderson, Department of Clinical Immunology, University of Göteborg, Sweden), with a predominant transparent phenotype, was used in this study for i.n. inoculation in the chinchilla model of OM and has been described in detail previously (1, 28, 29) .
Immunization of chinchillas with gel-purified recombinant neuraminidase. Thirty-five juvenile (200 to 300 g, either sex) chinchillas (Chinchilla lanigera) from Moulton Chinchilla Ranch (Rochester, MN) were each immunized by subcutaneous injec-tion of 100 g of the rNanA preparations as described previously (5, 17) . Briefly, the homogenized gel solution containing neuraminidase was diluted with an equal volume of Freund's complete adjuvant. Two additional booster immunizations of Freund's incomplete adjuvant, with the same doses of neuraminidase, were given at 1-month intervals. The control cohort of 35 chinchillas was immunized with concentrated eluate from the transformant control (without the NanA insert; it was subjected to the same expression, induction, and purification procedures as previously described [17] ). Blood for sera was obtained from all animals prior to the primary immunization, again at 2 weeks following the final boost, and at each date point when they were evaluated for NP colonization and OM.
Serum antibody response determined by ELISA and Western blotting. Titers of antibody against rNanA were determined by enzyme-linked immunosorbent assay (ELISA) as described previously (7) . Each well was coated with 0.5 g purified rNanA. Whole S. pneumoniae 6A was also used as the solid-phase antigen to determine the antibody titer to S. pneumoniae 6A as previously described (19) . Western blottings were also performed, using purified rNanA (2 g per lane) as previously described (17) .
Assessment of NP colonization and the development of OM after i.n. challenge with S. pneumoniae. Fourteen days following the final immunization with rNanA, both the experimental and sham-immunized control groups were inoculated i.n. with 5 ϫ 10 7 CFU of S. pneumoniae 6A in a volume of 0.2 ml as previously described (17) . Five chinchillas from each cohort, preseselected and randomized, were evaluated by tympanocentesis and nasal lavage on days 1, 3, 7, 10, 14, 21, and 28 postinoculation with 6A as previously described (28) . The middle ear and nasal lavage samples were cultured overnight on Columbia agar plates at 37°C with 5% CO 2 , and the number of CFU per milliliter was determined by a standard dilution assay and plate counting. Animals with significant tympanic membrane inflammation and middle ear fluid were considered to have developed OM as described previously (28) .
Statistical analysis. Data are expressed as medians Ϯ standard errors. Bacterial culture results below the detection limit of the viable-cell-count assay (10 CFU/ml) were ascribed values just below the detection limit (9 CFU/ml). Differences in S. pneumoniae concentrations in nasal and middle ear lavage samples between the cohorts immunized with rNanA and those treated with the buffer alone were analyzed by use of the Mann-Whitney rank sum test. Differences in the incidences of OM were analyzed by use of chi-square or Fisher-exact analysis. A P of Ͻ0.05 was set as the level of significance.
Effect of rNanA immunization on the kinetics of NP colonization. The relative ability of S. pneumoniae to colonize and persist in the nasopharynx for up to 28 days after i.n. challenge is shown in Fig. 1 . There was a statistically significant reduction in the bacterial concentration in the rNanA-immunized cohort compared with that in the control group on days 1, 3, 7, and 10 postinoculation. By day 1, the median concentrations of S. pneumoniae (CFU/ml) for nasal-lavage samples were 8.0 ϫ 10 4 and 1.1 ϫ 10 5 for animals immunized with rNanA and sham-immunized controls, respectively (P ϭ 0.016). By day 3, concentrations were 6.5 ϫ 10 4 and 1.7 ϫ 10 6 (P ϭ 0.008); by day 7, 5.0 ϫ 10 4 and 3.5 ϫ 10 5 (P ϭ 0.008); and by day 10, 7.6 ϫ 10 3 and 2.1 ϫ 10 5 (P ϭ 0.008). Pneumococci were eliminated from three of the five chinchillas in the rNanA-immunized group by day 14, whereas the bacteria persisted in the nasopharyx in all five chinchillas of the control cohort. By day 21, no pneumococci were present in the lavage samples from the immunized cohort, whereas the bacteria persisted in the nasopharynxes of all five control animals. Throughout the duration of the experiment, pneumococci persisted in the nasopharynx at a significantly higher concentration in the control cohort than that of the rNanA-immunized group and exhibited a gradual but steady decline. By day 28 postinoculation, pneumococci were eliminated from the nasopharynx in both cohorts. Effect of rNanA immunization on the development of OM. OM developed during the first week after i.n. inoculation of S. pneumoniae (Fig. 2) . Two chinchillas from each cohort developed OM on day 1; however, six chinchillas (nine ears infected) from the sham-inoculated control cohort developed OM compared with two chinchillas (two ears infected) in the rNanA-immunized cohort on days 3 and 7 after i.n. challenge (P was 0.034, based on the number of ears infected). Overall, immunization with rNanA resulted in a 50% reduction in the incidence of OM relative to that in sham-immunized controls. In the cohort receiving rNanA, only 4 of 35 chinchillas (11.4%) developed OM. In contrast, for sham-immunized animals, 8 of 35 chinchillas (22.9%) developed OM. However, there was no statistically significant difference in the incidences of OM between these two cohorts.
The median concentrations of S. pneumoniae cells for middle ear lavage samples from all animals in each cohort with positive bacterial culture were 2.4 ϫ 10 4 and 1.1 ϫ 10 5 for animals immunized with rNanA and sham-immunized controls, respectively (P ϭ 0.045).
Analysis of chinchilla serum antibody response. The sera were analyzed for anti-rNanA by ELISA. Chinchillas immunized with rNanA exhibited a strong specific antibody response to rNanA and demonstrated a reciprocal titer of Ն10 4 against FIG. 1. Nasopharyngeal colonization dynamics in chinchillas challenged intranasally with S. pneumoniae 6A in the sham control cohort or cohort immunized with rNanA. Each data point represents the median number of CFU of S. pneumoniae bacteria Ϯ the standard error of the median per milliliter of nasal lavage fluid from a total of five animals. *, P Ͻ 0.05; **, P Ͻ 0.01 compared to the value for the rNanA group. The dash line represents the detection limit of the assay.
rNanA by 2 weeks after the final boost immunization, and the level of specific serum antibody to rNanA was maintained up to day 28 postinoculation with S. pneumoniae 6A. Serum collected from animals prior to the start of the experiment (prebleeds) as well as serum from sham-inoculated controls contained no detectable activity when tested at a 1:50 dilution. These data indicate that a higher anti-rNanA antibody titer in the immunized cohort may contribute to the lower level of pneumococcal NP colonization than that of the controls.
Antiserum generated in chinchillas immunized with rNanA recognized the 100-kDa protein band associated with neuraminidase enzymatic activity in Western blots (data not shown), and titers for antiserum against rNanA were typically in excess of 1:100,000. Serum collected from animals prior to the start of the experiment (prebleeds) as well as serum from sham-inoculated controls contained no detectable activity when tested at a 1:100 dilution.
In order to rule out the possibility that an anti-S. pneumoniae 6A antibody response induced subsequent to the i.n. challenge may be responsible for pneumococcal clearance from the nasopharynx, serum antibody against whole S. pneumoniae 6A was measured. Antibody directed against S. pneumoniae 6A was not detectable at the first week postinoculation and was detected only with low reciprocal titers (100 to 200) by days 14, 21, and 28 postinoculation in both the immunized and control cohorts. There was no correlation between this antibody titer and the level of pneumococcal colonization in both the rNanA-immunized and the sham-immunized control cohort (Fig. 3) .
Two open reading frames in S. pneumoniae are known to produce proteins with neuraminidase activity. Both nanA and nanB have been cloned and sequenced (2, 6) . The activity of NanA is approximately 100 times higher than that of NanB against the flurogenic substrate (2). NanA contains an LPXTG in the C terminus and is linked covalently to the cell surface in a sortase-dependent manner (22) . Moreover, nanA expression is correlated to S. pneumoniae opacity phenotypes. Compared to what occurs in opaque variants, up-regulated nanA expression and increased NanA activity were observed in S. pneumoniae transparent variants that are selected for in vivo during NP colonization (12) .
We have proposed that NanA is involved in pneumococcal NP colonization in the chinchilla OM model (27) . A recent study by Orihuela et al. demonstrates that NanA contributes to colonization of the nasopharynx and to the spread of pneumococci from the nasopharynx to the lungs in a mouse model (21) . In contrast to these results, King et al. (12) reported that NanA does not appear to contribute to pneumococcal adherence to epithelial cells in vitro or to colonization in an infant rat model. However, they observed that the NanA-dependent desialylation of human airway glycoproteins, which bind to S. pneumoniae, may mediate bacterial clearance (12) .
Despite the contradictory data regarding the role of NanA in NP colonization in different animal models, the investigation of NanA as a protective antigen and a protein-based vaccine candidate warrants further investigation (11, 23, 26) . In an earlier study, native pneumococcal neuraminidase was evaluated as a protective antigen in an S. pneumoniae intraperitoneal infection model using mice (16) . A comparison between neuraminidase and pneumolysin revealed that although inoculation with purified neuraminidase afforded significant protection against systemic infection and death relative to what occurred in sham-inoculated controls, it was not as effective as pneumolysin. Furthermore, immunization with neuraminidase did not prevent mortality following intraperitoneal inoculation with S. pneumoniae. Our previous studies, however, indicate that the role of neuraminidase as a protective antigen appears to be anatomically niche specific and that it induces significant protection against pneumococcal OM (17) . An antecedent influenza A virus infection was used in combination with S. pneumoniae to induce OM in chinchillas during these studies. Influenza A virus plays a significant role in the increased pneumococcal NP colonization and incidence of OM, and this combined infection model is well established (28) . Influenza virus neuraminidase, however, has been suggested to be an (24) and may have masked the full effect of immunization with rNanA by removing the sialic acid substrate prior to challenge with S. pneumoniae. In the present study, we evaluated rNanA as a protective antigen against pneumococcal NP colonization and the development of OM without a concurrent influenza A virus infection in order to define the role of antineuraminidase antibody against S. pneumoniae alone. Our data show that pneumococci colonized the nasopharynx at a statistically significant lower level in the rNanA-immunized cohort than in the controls during the 28-day observation period. In addition, results from the present study indicate that specific immune responses against rNanA were associated with decreased duration of nasopharyngeal colonization. However, the bacteria were not completely eliminated until day 21 postinoculation, which may suggest the relatively subtle effects of rNanA immunization in this animal model. Pneumococcal virulence factors other than NanA contributing to NP colonization may be responsible for the bacterial persistence at the nasopharynx.
Data from the present study strongly suggest that anti-rNanA antibody may enhance host clearance or inhibit pneumococcal colonization. We have shown that NanA has a significant impact on the changes of the carbohydrate moieties in the eustachian tube epithelium and may be responsible for an increased ability to colonize the nasopharynx and invade the middle ear (30) . However, the mechanisms responsible for the effects of NanA need to be further explored. In conclusion, our results demonstrate the potential of NanA as a protective immunogen for pneumococcal diseases.
